The aim of the study was to perform a complex pharmacoepidemiological (???/DDD method of the WHO) and pharmacoeconomic analysis of the influence of APDs on a budget of in-patient psychiatric facilities. The present study was based on the WHO methodology on drug statistics (ATC/DDD-analysis) and budget impact analysis. The authors developed the tool of cost calculation via the cost of 1 DDD, which can be used at planning hospital budget on drugs. Costs for drugs were estimated from the national hospitals’ sources (2015). Initially, 8.5% of patients were treated with atypical long-acting injectable fluphenazine (FLU LAI) and 13% with oral chlorpromazine (CHL). The results of the study showed that FLU LAI had lower a cost of therapy, calculated per DDD dose, and was more effective in preventing relapse in schizophrenic patients in comparison with CHL (OR 0.31, CI 95% 0.11-0.88). If the proportion of patients, receiving FLU LAI increases by 1% while the proportion of patients, receiving CHL decreases by the same 1%, the total costs of medicines will decrease by 0.1%. If the proportion of patients treated with FLU LAI increases by 5% and 10% (and CHL decreases in the same proportion) the budget economy will be 0.5% and 1%, respectively. The proposed approach can be used for budget impact pharmacoeconomic analysis during budget planning at in-patient psychiatric facilities.
MA3 Paliperidone Palmitate Long-Acting Injection for Brazilian Non-Adherent Schizophrenic Patients: 5-Year Budget Impact Analysis From the Public Payer Perspective
